Madrigal Pharmaceuticals Inc (MDGL)
EBITDA Growth
-28.41%
Quarterly · Period ending:
MDGL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-28.41%period ending
Latest reported-28.41%period ending
MDGL Quarterly EBITDA YoY % (-231.40% → -28.41%)
Year-over-year change
High-resolution chart · PNG
MDGL ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -28.411% | |
| -23.8981% | |
| 10.2027% | |
| -3.2956% | |
| 73.9004% | |
| 51.5366% | |
| 48.5997% | |
| -8.2922% | |
| -78.8603% | |
| -92.8301% | |
| -28.524% | |
| -19.5127% | |
| -18.518% | |
| -29.6546% | |
| -30.4936% | |
| -26.3019% | |
| -13.4466% | |
| -8.5972% | |
| -8.4187% | |
| -7.3835% | |
| -22.6042% | |
| -39.5618% | |
| -98.6199% | |
| -174.1507% | |
| -155.259% | |
| -151.6609% | |
| -161.3624% | |
| -152.1324% | |
| -205.6401% | |
| -137.3758% | |
| -36.5534% | |
| -1.604% | |
| 22.8205% | |
| -5.7016% | |
| -8.1127% | |
| -305.9794% | |
| -215.9909% | |
| -766.9019% | |
| 24.119% | |
| -134.1001% | |
| 86.3519% | |
| 96.568% | |
| 48.1825% | |
| 95.4413% | |
| 10.1988% | |
| 11.3286% | |
| 15.347% | |
| 10.9212% | |
| 1.8507% | |
| -12.8038% | |
| -32.4824% | |
| -50.6437% | |
| -57.7025% | |
| -40.6209% | |
| -76.7994% | |
| -21.0735% | |
| -19.6645% | |
| -36.1736% | |
| -25.8922% | |
| -21.6233% | |
| -35.7744% | |
| -20.4049% | |
| -22.2274% | |
| -108.2575% | |
| -9.7411% | |
| 59.3462% | |
| 74.3279% | |
| 559.42% | |
| 65.0432% | |
| -21.0446% | |
| -62.8492% | |
| -76.5651% | |
| -34.3062% | |
| -9.5781% | |
| -26.9831% | |
| 0.0617% | |
| -11.321% | |
| -8.6147% | |
| 21.3917% | |
| 45.3759% | |
| 44.0606% | |
| 17.3788% | |
| -231.4013% |